Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis

References

• Anderson ARA, Weaver AM, Cummings PT, Quaranta V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 2006; 127:905-15; PMID:17129778; http://dx.doi.org/10.1016/j.cell.2006.09.042
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22:329-60; PMID:15032581; http://dx.doi.org/10.1146/annurev.immunol.22.012703.104803
   PubMed Web of Science ®Google Scholar
• Swartz MA, Lund AW. Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nat Rev Cancer 2012; 12:210-9; PMID:22362216; http://dx.doi.org/10.1038/nrc3186
   PubMed Web of Science ®Google Scholar
• Serrano A, Castro-Vega I, Redondo M. Role of gene methylation in antitumor immune response: implication for tumor progression. Cancers 2011; 3:1672-90; PMID:24212778; http://dx.doi.org/10.3390/cancers3021672
   PubMedGoogle Scholar
• Janikashvili N, Bonnotte B, Katsanis E, Larmonier N. The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin Dev Immunol 2011; 2011:14; http://dx.doi.org/10.1155/2011/430394
   Web of Science ®Google Scholar
• Paschen A, Méndez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, Garrido F, Schadendorf D. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 2003; 103:759-67; http://dx.doi.org/10.1002/ijc.10906
   PubMed Web of Science ®Google Scholar
• Campoli M, Ferrone S. Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens 2008; 72:321-34; PMID:18700879; http://dx.doi.org/10.1111/j.1399-0039.2008.01106.x
   PubMed Web of Science ®Google Scholar
• Browning M, Dunnion D. HLA and cancer: implications for cancer immunotherapy and vaccination. Eur J Immunogenet 1997; 24:293-312; PMID:9306099; http://dx.doi.org/10.1111/j.1365-2370.1997.tb00025.x
   PubMedGoogle Scholar
• Sioud M. Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines? Scand J Immunol 2009; 70:516-25; PMID:19906192; http://dx.doi.org/10.1111/j.1365-3083.2009.02326.x
   PubMed Web of Science ®Google Scholar
• Garrido F, Cabrera T, Aptsiauri N. “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 2010; 127:249-56; PMID:20178101; http://dx.doi.org/10.1002/ijc.25270#
   PubMed Web of Science ®Google Scholar
• Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 2008; 57:1719-26; PMID:18408926; http://dx.doi.org/10.1007/s00262-008-0515-4
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006; 90:1-50; PMID:16730260; http://dx.doi.org/10.1016/S0065-2776(06)90001-7
   PubMed Web of Science ®Google Scholar
• Gamzatova Z, Villabona L, van der Zanden H, Haasnoot GW, Andersson E, Kiessling R, Seliger B, Kanter L, Dalianis T, Bergfeldt K et al. Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer. Tissue Antigens 2007; 70:205-13; PMID:17661908; http://dx.doi.org/10.1111/j.1399-0039.2007.00875.x
   PubMed Web of Science ®Google Scholar
• Helgadottir H, Andersson E, Villabona L, Kanter L, van der Zanden H, Haasnoot GW, Seliger B, Bergfeldt K, Hansson J, Ragnarsson-Olding B et al. The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma. Cancer Immunol Immunother 2009; 58:1599-608; PMID:19214504; http://dx.doi.org/10.1007/s00262-009-0669-8
   PubMed Web of Science ®Google Scholar
• De Petris L, Bergfeldt K, Hising C, Lundqvist A, Tholander B, Pisa P, van der Zanden HG, Masucci G. Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates. Med Oncol 2004; 21:49-52; PMID:15034213; http://dx.doi.org/10.1385/MO:21:1:49
   PubMed Web of Science ®Google Scholar
• Norell H, Carlsten M, Ohlum T, Malmberg KJ, Masucci G, Schedvins K, Altermann W, Handke D, Atkins D, Seliger B et al. Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. Cancer Res 2006; 66:6387-94; PMID:16778217; http://dx.doi.org/10.1158/0008-5472.CAN-06-0029
   PubMed Web of Science ®Google Scholar
• Villabona L, Leon Rodriguez DA, Andersson EK, Seliger B, Dalianis T, Masucci GV. A novel approach for HLA-A typing in formalin-fixed paraffin-embedded-derived DNA. Mod Pathol 2014; 27:1296-305; PMID:24504073; http://dx.doi.org/10.1038/modpathol.2013.210
   PubMed Web of Science ®Google Scholar
• So T, Takenoyama M, Sugaya M, Yasuda M, Eifuku R, Yoshimatsu T, Osaki T, Yasumoto K. Unfavorable prognosis of patients with non-small cell lung carcinoma associated with HLA-A2. Lung Cancer 2001; 32:39-46; PMID:11282427; http://dx.doi.org/10.1016/S0169-5002(00)00204-X
   PubMed Web of Science ®Google Scholar
• Rogentine CN, Jr., Dellon AL, Chretien PB. Prolonged disease-free survival in bronchogenic carcinoma associated with HLA-Aw19 and HLA-B5. A two-year prospective study. Cancer 1977; 39:2345-7; PMID:872033; http://dx.doi.org/10.1002/1097-0142(197706)39:6%3c2345::AID-CNCR2820390605%3e3.0.CO;2-W
   PubMed Web of Science ®Google Scholar
• Tisch M, Kyrberg H, Weidauer H, Mytilineos J, Conradt C, Opelz G, Maier H. Human leukocyte antigens and prognosis in patients with head and neck cancer: results of a prospective follow-up study. Laryngoscope 2002; 112:651-7; PMID:12150518; http://dx.doi.org/10.1097/00005537-200204000-00011
   PubMed Web of Science ®Google Scholar
• Menier C, Saez B, Horejsi V, Martinozzi S, Krawice-Radanne I, Bruel S, Le Danff C, Reboul M, Hilgert I, Rabreau M et al. Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol 2003; 64:315-26; PMID:12590976; http://dx.doi.org/10.1016/S0198-8859(02)00821-2
   PubMed Web of Science ®Google Scholar
• Rouas-Freiss N, Moreau P, LeMaoult J, Carosella ED. The dual role of HLA-G in cancer. J Immunol Res 2014; 2014:359748; PMID:24800261; http://dx.doi.org/10.1155/2014/359748
   PubMed Web of Science ®Google Scholar
• Crisa L, McMaster MT, Ishii JK, Fisher SJ, Salomon DR. Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J Exp Med 1997; 186:289-98; PMID:9221758; http://dx.doi.org/10.1084/jem.186.2.289
   PubMed Web of Science ®Google Scholar
• Le Discorde M, Moreau P, Sabatier P, Legeais JM, Carosella ED. Expression of HLA-G in human cornea, an immune-privileged tissue. Hum Immunol 2003; 64:1039-44; PMID:14602233; http://dx.doi.org/10.1016/j.humimm.2003.08.346
   PubMed Web of Science ®Google Scholar
• Cirulli V, Zalatan J, McMaster M, Prinsen R, Salomon DR, Ricordi C, Torbett BE, Meda P, Crisa L. The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLA-G. Diabetes 2006; 55:1214-22; PMID:16644675; http://dx.doi.org/10.2337/db05-0731
   PubMed Web of Science ®Google Scholar
• Menier C, Rabreau M, Challier JC, Le Discorde M, Carosella ED, Rouas-Freiss N. Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis. Blood 2004; 104:3153-60; PMID:15284117; http://dx.doi.org/10.1182/blood-2004-03-0809
   PubMed Web of Science ®Google Scholar
• Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol 2003; 81:199-252; PMID:14711057; http://dx.doi.org/10.1016/S0065-2776(03)81006-4
   PubMed Web of Science ®Google Scholar
• Rouas-Freiss N, Moreau P, Menier C, LeMaoult J, Carosella ED. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol 2007; 17:413-21; PMID:17881247; http://dx.doi.org/10.1016/j.semcancer.2007.07.003
   PubMed Web of Science ®Google Scholar
• Riteau B, Faure F, Menier C, Viel S, Carosella ED, Amigorena S, Rouas-Freiss N. Exosomes bearing HLA-G are released by melanoma cells. Hum Immunol 2003; 64:1064-72; PMID:14602237; http://dx.doi.org/10.1016/j.humimm.2003.08.344
   PubMed Web of Science ®Google Scholar
• Kleinberg L, Florenes VA, Skrede M, Dong HP, Nielsen S, McMaster MT, Nesland JM, Shih Ie M, Davidson B. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch 2006; 449:31-9; PMID:16541284; http://dx.doi.org/10.1007/s00428-005-0144-7
   PubMed Web of Science ®Google Scholar
• Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res 2005; 65:10139-44; PMID:16287995; http://dx.doi.org/10.1158/0008-5472.CAN-05-0097
   PubMed Web of Science ®Google Scholar
• Joly E, Hudrisier D. What is trogocytosis and what is its purpose? Nat Immunol 2003; 4:815; PMID:12942076; http://dx.doi.org/10.1038/ni0903-815
   PubMed Web of Science ®Google Scholar
• Carosella ED, Favier B, Rouas-Freiss N, Moreau P, Lemaoult J. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 2008; 111:4862-70; PMID:18334671; http://dx.doi.org/10.1182/blood-2007-12-127662
   PubMed Web of Science ®Google Scholar
• Tomasec P, Braud VM, Rickards C, Powell MB, McSharry BP, Gadola S, Cerundolo V, Borysiewicz LK, McMichael AJ, Wilkinson GW. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 2000; 287:1031; PMID:10669413; http://dx.doi.org/10.1126/science.287.5455.1031.
   PubMed Web of Science ®Google Scholar
• Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M, Geraghty DE. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A 1998; 95:5199-204; PMID:9560253; http://dx.doi.org/10.1073/pnas.95.9.5199
   PubMed Web of Science ®Google Scholar
• Wei XH, Orr HT. Differential expression of HLA-E, HLA-F, and HLA-G transcripts in human tissue. Hum Immunol 1990; 29:131-42; PMID:2249951; http://dx.doi.org/10.1016/0198-8859(90)90076-2
   PubMed Web of Science ®Google Scholar
• Marin R, Ruiz-Cabello F, Pedrinaci S, Mendez R, Jimenez P, Geraghty DE, Garrido F. Analysis of HLA-E expression in human tumors. Immunogenetics 2003; 54:767-75; PMID:12618909
   PubMed Web of Science ®Google Scholar
• Hoare HL, Sullivan LC, Clements CS, Ely LK, Beddoe T, Henderson KN, Lin J, Reid HH, Brooks AG, Rossjohn J. Subtle changes in peptide conformation profoundly affect recognition of the non-classical MHC class I molecule HLA-E by the CD94-NKG2 natural killer cell receptors. J Mol Biol 2008; 377:1297-303; PMID:18339401; http://dx.doi.org/10.1016/j.jmb.2008.01.098
   PubMed Web of Science ®Google Scholar
• Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998; 391:795-9; PMID:9486650; http://dx.doi.org/10.1038/35869
   PubMed Web of Science ®Google Scholar
• Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K, Rabbani H, Moretta A, Soderstrom K, Levitskaya J et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest 2002; 110:1515-23; PMID:12438449; http://dx.doi.org/10.1172/JCI0215564
   PubMed Web of Science ®Google Scholar
• Marchesi M, Andersson E, Villabona L, Seliger B, Lundqvist A, Kiessling R, Masucci GV. HLA-dependent tumour development: a role for tumour associate macrophages? J Transl Med 2013; 11:247; PMID:24093459; http://dx.doi.org/10.1186/1479-5876-11-247
   PubMed Web of Science ®Google Scholar
• Pietra G, Romagnani C, Manzini C, Moretta L, Mingari MC. The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune response to pathogens and tumors. J Biomed Biotechnol 2010; 2010:907092; PMID:20634877; http://dx.doi.org/10.1155/2010/907092
   PubMed Web of Science ®Google Scholar
• Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, Seliger B, Masucci GV. Correlation of HLA-A02* genotype and HLA class I antigen downregulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother 2012; 61:1243-53; PMID:22258792; http://dx.doi.org/10.1007/s00262-012-1201-0
   PubMed Web of Science ®Google Scholar
• Gamzatova Z, Villabona L, Dahlgren L, Dalianis T, Nillson B, Bergfeldt K, Masucci GV. Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecol Oncol 2006; 103:145-50; PMID:16542716; http://dx.doi.org/10.1016/j.ygyno.2006.02.004
   PubMed Web of Science ®Google Scholar
• Park B, Lee S, Kim E, Chang S, Jin M, Ahn K. The truncated cytoplasmic tail of HLA-G serves a quality-control function in post-ER compartments. Immunity 2001; 15:213-24; PMID:11520457; http://dx.doi.org/10.1016/S1074-7613(01)00179-0
   PubMed Web of Science ®Google Scholar
• Gooden M, Lampen M, Jordanova ES, Leffers N, Trimbos JB, van der Burg SH, Nijman H, van Hall T. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes. Proc Natl Acad Sci 2011; 108:10656-61; PMID:3127933; http://dx.doi.org/10.1073/pnas.1100354108
   PubMed Web of Science ®Google Scholar
• Polakova K, Kuba D, Russ G. The 4H84 monoclonal antibody detecting beta2m free nonclassical HLA-G molecules also binds to free heavy chains of classical HLA class I antigens present on activated lymphocytes. Hum Immunol 2004; 65:157-62; PMID:14969770; http://dx.doi.org/10.1016/j.humimm.2003.10.005
   PubMed Web of Science ®Google Scholar
• Polakova K, Bennink JR, Yewdell JW, Bystricka M, Bandzuchova E, Russ G. Mild acid treatment induces cross-reactivity of 4H84 monoclonal antibody specific to nonclassical HLA-G antigen with classical HLA class I molecules. Hum Immunol 2003; 64:256-64; PMID:12559628; http://dx.doi.org/10.1016/S0198-8859(02)00777-2
   PubMed Web of Science ®Google Scholar
• Kochan G, Escors D, Breckpot K, Guerrero-Setas D. Role of non-classical MHC class I molecules in cancer immunosuppression. Oncoimmunology 2013; 2:e26491; PMID:24482746; http://dx.doi.org/10.4161/onci.26491
   PubMedGoogle Scholar
• Lin A, Chen HX, Zhu CC, Zhang X, Xu HH, Zhang JG, Wang Q, Zhou WJ, Yan WH. Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma. J Cell Mol Med 2010; 14:2162-71; PMID:19799650; http://dx.doi.org/10.1111/j.1582-4934.2009.00917.x
   PubMed Web of Science ®Google Scholar
• McCormick J, Whitley GS, Le Bouteiller P, Cartwright JE. Soluble HLA-G regulates motility and invasion of the trophoblast-derived cell line SGHPL-4. Hum Reprod 2009; 24:1339-45; PMID:19223288; http://dx.doi.org/10.1093/humrep/dep026
   PubMed Web of Science ®Google Scholar
• Morandi F, Airoldi I, Pistoia V. IL-27 driven upregulation of surface HLA-E expression on monocytes inhibits IFN-gamma release by autologous NK cells. J Immunol Res 2014; 2014:938561; PMID:24741633; http://dx.doi.org/10.1155/2014/938561
   PubMed Web of Science ®Google Scholar
• Clements CS, Kjer-Nielsen L, Kostenko L, Hoare HL, Dunstone MA, Moses E, Freed K, Brooks AG, Rossjohn J, McCluskey J. Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal-maternal interface. Proc Natl Acad Sci U S A 2005; 102:3360-5; PMID:15718280; http://dx.doi.org/10.1073/pnas.0409676102
   PubMed Web of Science ®Google Scholar
• Menier C, Prevot S, Carosella ED, Rouas-Freiss N. Human leukocyte antigen-G is expressed in advanced-stage ovarian carcinoma of high-grade histology. Hum Immunol 2009; 70:1006-9; PMID:19660509; http://dx.doi.org/10.1016/j.humimm.2009.07.021
   PubMed Web of Science ®Google Scholar
• Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 2003; 171:1918-26; PMID:12902494; http://dx.doi.org/10.4049/jimmunol.171.4.1918
   PubMed Web of Science ®Google Scholar
• Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT et al. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 2008; 14:3372-9; PMID:18519766; http://dx.doi.org/10.1158/1078-0432.CCR-07-4433
   PubMed Web of Science ®Google Scholar